Abstract
The transmissible spongiform encephalopathies (TSE ) comprise a spectrum of diseases in animals and man. Scrapie was first described over 200 years ago and is endemic in sheep and goats throughout large parts of the world. There is no evidence, however, that it has ever transmitted to man. Chronic Wasting Disease is endemic in Rocky Mountain Elk and Mule Deer in the USA and again there is no direct good evidence that it is transmissible to man. Transmissible Mink Encephalopathy (TME ) described in farmed mink in Wisconsin, may have been transmitted via contaminated food. Bovine Spongiform Encephalopathy (BSE ) was first described in the United Kingdom in 1985. Infected cattle display characteristic clinical features in which they become hypersensitive, ataxic and difficult to handle, hence giving rise to the colloquial name “Mad Cow Disease”. It is thought that the disease either arose spontaneously in cattle or was transmitted from scrapie infected sheep, and was thereafter propagated via rendered meat and bone meal products. More than 180,000 clinical cases of BSE have been described to date in the UK, and although the incidence of the disease continues to decline, 1,300 further cases were described in 2000. It is thought that up to another 750,000 cases of BSE could have entered the human food chain prior to the development of clinical disease. About 1,500 cases of BSE have been described in other European countries thus far. Natural and experimental transmission of BSE has occurred in up to twenty different species including domestic and exotic cats and exotic ungulates in British zoos.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921–25.
Zeidler M, Stewart GE, Barraclough CR et al. New variant CreutzfeldtJakob disease: neurologic features and diagnostic tests. Lancet 1997; 350: 903–07.
Zeidler M, Johnstone EC, Bamber RWK et al. New variant CreutzfeldtJakob disease: psychiatric features. Lancet 1997; 350: 908–10.
Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354: 317–23.
Bruce M. New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Nat Med. 2000; 3: 258–59.
Brown P, Will RG, Barclay R et al. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution and current concerns. Emerg Infect Dis 2001; 7: 6–16.
Lasmezas CL, Deslys JP, Demalmay R et al. BSE transmission to macaques. Nature 1996; 381: 743–44.
Collinge J, Sidle KCL, Meads J et al. Molecular analysis of prion strain variation and etiology of `new variant’ CJD. Nature 1996; 383: 685–90.
Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that `new variant’ CJD is caused by the BSE agent. Nature 1997; 389: 498–501.
Hill AF, Desbruslais M, Joiner S et al. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448–50.
Scott MR, Will RG, Ironside JW et al. Compelling transgenic evidence for transmission of bovine spongiform encephalopathy to humans. Proc Natl Acad Sci USA 1999; 96: 15137–42.
Cousens S, Vynnycky E, Zeidler M et al. Predicting the CJD epidemic in humans. Nature 1997; 385: 197–98.
Ghani AC, Ferguson NM, Donnelly CA et al. Predicted vCJD mortality in Great Britain. Nature 2000; 406: 583–84.
Ironside JW, Head MW, Bell JE et al. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology 2000; 37: 1–9.
Barclay GR, Hope J, Birkett CR et al. Distribution of cell associated prion protein in normal adult blood determined by flow cytometry. Brit J Haematol 1999; 107: 804–14.
Macgregor I, Hope J, Barnard G et al. The distribution of normal prion protein in human blood. Vox Sang 1999; 77: 88–96.
Hill AF, Butterworth RJ, Joiner S et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183–89.
Hilton DA, Fathers E, Edwards P et al. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703–04.
Brown P. The pathogenesis of transmissible spongiform encephalopathy: routes to the brain and the erection of therapeutic barriers. Cell Mol Life Sci 2001; 58: 259–65.
Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 2001; 137: 5–13.
Brown P, Rohwer RG, Dunstan BC et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810–16.
Brown P, Cervenakova L, McShane LM et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169–78.
Rohwer RG. Titer distribution and transmissibility of blood-borne TSE infectivity. Cambridge Healthtech Institute 6th Annual Meeting. Blood Product Safety: TSE perception vs Reality. Virginia, USA. Feb 13–15, 2000.
Houston F, Foster JD, Chong A et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999–1000.
Brown P. Transfusion medicine and spongiform encephalopathy. Transfusion 2001; 41: 433–36.
Andrews NJ, Farrington CP, Cousens SN et al. Incidence of variant Creutzfeldt-Jakob disease in the UK. Lancet 2000; 356: 481–82.
Cousens S, Smith PG, Ward H et al.: Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994–2000. Lancet 2001; 357: 1002–07.
Bryant G, Monk P Summary of the final report of the investigation into the North Leicestershire cluster of variant Creutzfeldt-Jakob disease. Leicestershire NHS Health Authority 2001.
Otto M, Wiltfang J, Schutz E et al. Diagnosis of Creutzfeldt-Jakob disease by measurement of S 100 protein in serum: prospective case control study. B M J 1998; 316: 577–82.
Miele G, Manson J, Clinton M. A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat Medicine 2001; 7: 361–64
Korth C, Stierli B, Streit P et al. Prion (PrPSc) specific epitope defined by a monoclonal antibody. Nature 1997; 390: 74–77.
Fischer MB, Roeckl C, Parizek P et al. Binding of disease-associated prion protein to plasminogen. Nature 2000; 408: 479–83.
Lee DC, Stenland CJ, Hartwell RC et al. Monitoring plasma processing steps with a sensitive Western Blot assay for the detection of the prion protein. J Virol Methods 2000; 84: 77–79.
Schmerr MJ, Jenny AL, Bulgin MS et al. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatography 1999; 853: 207–14.
Safar J, Willie H, Itri V et al. Eight prion strains have PrP$0 molecules with different conformations. Nat Med 1998; 4: 1157–65.
Roddie PH, Turner ML, Williamson LM. Leucocyte depletion of blood components. Blood Rev 2000; 14: 145–56.
Priola SA, Caughey B, Caughey WS. Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies. Cur Opin Microbiol 1999; 2: 563–66.
Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 1999; 353: 117.
Korth C, May PC, Cohen FE et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98: 9836–41.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Turner, M.L. (2002). Rion Diseases and Blood Transfusion. In: Sibinga, C.T.S., Dodd, R.Y. (eds) Transmissible Diseases and Blood Transfusion. Developments in Hematology and Immunology, vol 37. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6869-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6869-5_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5233-2
Online ISBN: 978-1-4757-6869-5
eBook Packages: Springer Book Archive